RAC 2.92% $1.94 race oncology ltd

Ann: Zantrene AML trial in Israel advances to Phase 2, page-128

  1. 2,920 Posts.
    lightbulb Created with Sketch. 1297
    therefore the 505(b)(2) is a null point now as no future (or previously planned studies) are comparable to historical studies?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.